Results 51 to 60 of about 19,009 (196)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Decitabine Induced Transient Cardiomyopathy: A Case Report

open access: yes, 2012
Case Report A 75-yr-old gentleman, with a past medical history of diabetes mellitus and Acute Myeloid Leukemia presented to our emergency department with a chief complaint of exertional dyspnea and chest pain.
Chitradeep De   +6 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

open access: yesBMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang   +7 more
wiley   +1 more source

Optimization of decitabine treatment.

open access: yes, 2013
A, qRTPCR results showing MLH1 gene expression in RKO cells after treatment with the indicated concentration of decitabine. Cells were treated every 24 hours for a period of 72 hours. MLH1 expression was normalized to SDHA. B, Immunoblot of DNMT1 protein
Mathew A. Sloane (437526)   +6 more
core   +1 more source

Inhibiting DNA Methylation Improves Survival in Severe Sepsis by Regulating NF-κB Pathway

open access: yesFrontiers in Immunology, 2020
Organ dysfunction caused by sepsis is life-threatening and results in high mortality. Therapeutic options for sepsis are limited. Pathogenic factors are considered as components of environmental pressure that modify DNA methylation patterns thereby ...
Luxi Cao   +59 more
doaj   +1 more source

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

open access: yes, 2018
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
James Slack   +4 more
core   +1 more source

Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This review synthesizes the epigenetic mechanisms—DNA methylation, histone modifications, and non‐coding RNAs—that drive hepatic stellate cell activation and the progression of liver fibrosis. It further evaluates emerging therapeutic strategies targeting these epigenetic regulators, including DNA methyltransferase and histone deacetylase inhibitors ...
Maryam Jadid Tavaf   +8 more
wiley   +1 more source

Decitabine further enhances chidamide-induced PRAME upregulation and PRAME antigen-specific CTL cytotoxicity of THP-1 cells.

open access: yes, 2013
A. AML cell lines were treated with chidamde (1 µM), decitabine (Dac, 0.25 mM), or chidamide/decitabine. PRAME mRNA expression was analyzed by RT-qPCR. Y axis shows folds of PRAME mRNA expression relative to that of non-treated cells. B. THP-1 cells were
Lixin Wang (343011)   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy